Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN versus SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN versus SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH.
CHLOROMYCETIN vs SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. Sequential blockade produces bactericidal effect.
50-100 mg/kg/day IV divided every 6 hours; maximum 4 g/day. Topical: apply to affected area 2-4 times daily.
One double-strength tablet (160 mg trimethoprim/800 mg sulfamethoxazole) orally every 12 hours.
None Documented
None Documented
1.5-4 hours in adults; prolonged to 3-7 hours in neonates and 4-12 hours in hepatic impairment; clinical context: dose adjustment required in liver disease.
Sulfamethoxazole: 9-11 hours; trimethoprim: 8-11 hours. In severe renal impairment (CrCl <15 mL/min), half-life prolongs significantly (up to 30 hours for trimethoprim).
Renal: 5-10% unchanged; hepatic glucuronidation (90%) followed by renal elimination of metabolites; small biliary excretion (<5%) and fecal elimination.
Both sulfamethoxazole and trimethoprim are primarily excreted via the kidneys. Sulfamethoxazole: ~30% as unchanged drug, ~50% as N4-acetyl metabolite; trimethoprim: ~80% as unchanged drug. Fecal elimination is minimal (<5%).
Category C
Category D/X
Antibiotic
Antibiotic